Overview

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countries.
Phase:
Phase 3
Details
Lead Sponsor:
Orient Europharma Co., Ltd.
Collaborator:
NanoCarrier Co., Ltd.
Treatments:
Gemcitabine